Previous 10 | Next 10 |
Windtree Therapeutics ( OTCQB:WINT ): Q1 GAAP EPS of -$0.48. More news on: Windtree Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WARRINGTON, Pa. , April 28, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announ...
WARRINGTON, Pa. , April 6, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the p...
Windtree Therapeutics ( OTCQB:WINT ): Q4 GAAP EPS of -$0.21. More news on: Windtree Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WARRINGTON, Pa. , April 2, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported f...
WARRINGTON, Pa. , March 31, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announces it ha...
Windtree Therapeutics ( OTCQB:WINT ): planning to study its KL4 surfactant to potentially mitigate pulmonary effects of severe COVID-19 infection. More news on: Windtree Therapeutics, Inc., Enzo Biochem, Inc., Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Re...
WARRINGTON, Pa. , March 24, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announc...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
WARRINGTON, Pa. , Dec. 9, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, will host a con...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. Company Name:
WINT Stock Symbol:
OTCMKTS Market:
Windtree Therapeutics Inc. Website:
$12.9 Million Transaction Includes Approximately $3.4 Million of New Funding and a $9.5 Million Full Cancellation of Outstanding Senior Notes and Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WA...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...